Source: King’s College London, June 2025
New research identifies blood-based B cell and antibody signatures that could guide safer treatment for patients receiving immunotherapy.
Researchers at King’s College London have identified immune markers in the blood that could help predict which patients with melanoma are most likely to benefit from immunotherapy and which patients are at greater risk of experiencing serious immune-related side effects.
Immunotherapy has transformed the outlook for many cancer patients, including those with melanoma. However, for some, the treatment can trigger serious immune-related side effects that are severe enough to stop therapy altogether. Currently, doctors have no reliable way to predict in advance who will benefit from treatment and who is at risk of these harmful reactions.